Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2026)
Sutro Biopharma (STRO) posted Return on Capital Employed of 135.81% for Q4 2025, down 20.1% sequentially from 113.08% in Q3 2025, and down 5290.0% YoY from 2.62% in Q4 2024.
Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2026) Analysis & Trends
Sutro Biopharma has reported Return on Capital Employed for 8 years, with the latest figure at 135.81% in Q4 2025.
- Quarterly Return on Capital Employed fell 5290.0% year-over-year to 135.81% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 135.81% (down 5290.0% YoY) and the FY2025 annual result came in at 77.11%, up 316.0% from the prior year.
- Return on Capital Employed retreated to 135.81% in Q4 2025 per STRO's latest filing, from 113.08% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 19.3% in Q2 2021 and troughed at 135.81% in Q4 2025.
- A 5-year average of 52.75% and a median of 39.61% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2021 and 2025: Return on Capital Employed surged 2900 bps in 2021, then slumped 8417 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 31.31% in 2021, then retreated by 22 bps to 38.23% in 2022, then soared by 35 bps to 24.97% in 2023, then sank by 232 bps to 82.9% in 2024, then slumped by 64 bps to 135.81% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 135.81%, 113.08%, and 94.21% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | -91.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -91.23% |
| Dec 31, 2025 | -135.81% |
| Sep 30, 2025 | -113.08% |
| Jun 30, 2025 | -94.21% |
| Mar 31, 2025 | -113.15% |
| Dec 31, 2024 | -82.90% |
| Sep 30, 2024 | -38.34% |
| Jun 30, 2024 | -33.56% |
| Mar 31, 2024 | -28.98% |
| Dec 31, 2023 | -24.97% |
| Sep 30, 2023 | -48.48% |
| Jun 30, 2023 | -46.13% |
| Mar 31, 2023 | -40.88% |
| Dec 31, 2022 | -38.23% |
| Sep 30, 2022 | -34.27% |
| Jun 30, 2022 | -42.73% |
| Mar 31, 2022 | -41.81% |
| Dec 31, 2021 | -31.31% |
| Sep 30, 2021 | -26.75% |
| Jun 30, 2021 | -19.30% |